Sign in
Taking peoplePhase 3

Orphenadrine for muscle cramps in people with liver cirrhosis

Tests orphenadrine against placebo for muscle cramps in people with cirrhosis.

Key facts

Who runs it
Sherief Abd-Elsalam
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With Cirrhosis
Status
Recruiting
Phase
Phase 3
People taking part
100 people, planned
Started
Jan 2015
Expected to end
Dec 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • orphenadrine
  • Placebo
Record updated
7 June 2019

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with liver cirrhosis who have muscle cramps at least 3 times per week.

Sex
All sexes can join.
Disease stage
Liver cirrhosis with muscle cramps (≥3 cramps per week).
Earlier treatment
People taking calcium channel blockers, conjugated estrogens or naproxen cannot join.

Main reasons for not taking part

  • Allergy to orphenadrine
  • Kidney problems (renal impairment)
  • Pregnant or breastfeeding women
  • Poor blood flow in the limbs (peripheral vascular disease) or nerve damage in the limbs (peripheral neuropathy)
  • Glaucoma or an enlarged prostate

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Cirrhosis
  • Muscle cramps( ≥3 cramps per week )

Who cannot take part

  • • Allergy to orphenadrine; Renal impairment; Pregnant and lactating women; Peripheral vascular disease; Peripheral neuropathy; Medications as calcium channel blockers, conjugated estrogens and naproxen. Glaucoma Prostatic enlargement

This trial is currently available in Egypt.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Muscle cramps are common in patients with liver disease and associated with significantly diminished quality of life. Patients with cirrhosis often experience muscle cramps with varied frequency and severity. The exact mechanisms by which they occur remain unclear, although a number of pathophysiological events unique to liver disease may contribute. Clinical studies have identified alterations in 3 areas: nerve function, energy metabolism, and plasma volume/electrolytes (1) Orphenadrine is an anticholinergic drug with prominent central nervous system (CNS) and peripheral actions used to treat painful muscle spasms and other similar conditions. The combination of anticholinergic effects and CNS penetration make orphenadrine useful for pain of all etiologies, including from: radiculopathy, muscles, and headaches. [3,4]

The 2 groups in the trial

  • Orphenadrine(Norflex)Treatment being tested

    50 patients will be treated with orphenadrine 100 mg twice daily for 1 month

    Treatment: orphenadrine

  • PlaceboPlacebo, for comparison

    50 patients will be given placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With Cirrhosis
Plain-language title
Orphenadrine for muscle cramps in people with liver cirrhosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Publications
Record updated
7 June 2019